<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03277677</url>
  </required_header>
  <id_info>
    <org_study_id>IRB.113/60</org_study_id>
    <nct_id>NCT03277677</nct_id>
  </id_info>
  <brief_title>The Effect of Fluid Resuscitation With 0.9% Sodium Chloride Versus Balanced Crystalloid Solution on Renal Function of Sepsis Patients</brief_title>
  <official_title>The Effect of Fluid Resuscitation With 0.9% Sodium Chloride Versus Balanced Crystalloid Solution on Renal Function of Sepsis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The high chloride content of 0.9%sodium chloride (0.9%NaCl) leads to adverse&#xD;
      pathophysiological effects in both animals and healthy human volunteers. Small randomized&#xD;
      trials confirm that the hyperchloremic acidosis induced by 0.9%NaCl also occurs in patients.&#xD;
      A strong signal is emerging from recent large propensity-matched and cohort studies for the&#xD;
      adverse effects that 0.9% NaCl has on the clinical outcome in surgical and critically ill&#xD;
      patients when compared with balanced crystalloids. Major complications are the increased&#xD;
      incidences of acute kidney injury and the need for renal replacement therapy, and that&#xD;
      pathological hyperchloremia may increase postoperative mortality.&#xD;
&#xD;
      Fluid resuscitation with 0.9% NaCl in animals with sepsis resulted in hyperchloremic&#xD;
      metabolic acidosis, worsened AKI, and increased mortality when compared with resuscitation&#xD;
      with a balanced crystalloid solution.&#xD;
&#xD;
      Furthermore, hyperchloremic acidosis also resulted in increased concentrations of circulating&#xD;
      inflammatory mediators in an experimental model of severe sepsis in rats, with a&#xD;
      dose-dependent increase in circulating interleukin-6, tumor necrosis factor-a, and&#xD;
      interleukin-10 concentrations with increasing acidosis.&#xD;
&#xD;
      Thus, in this study, investigators compared the effects of a balanced crystalloid solution&#xD;
      with 0.9% NaCl on the renal function in severe sepsis/septic shock patients. Investigators&#xD;
      hypothesized that balanced crystalloid solution resuscitation would decrease AKI incidence&#xD;
      and severity and would improve immunomodulatory effect when compared with 0.9% NaCl&#xD;
      resuscitation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of acute kidney injury for any stage and severity</measure>
    <time_frame>at day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The neutrophil function (chemotaxis, CD11b ) between two randomized groups at</measure>
    <time_frame>0, 24, and 72 hours after resuscitation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The monocyte function (HLA-DR) between two randomized groupsafter resuscitation.</measure>
    <time_frame>at 0, 24, and 72 hours after resuscitation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The inflammatory marker (IL-6, IL-10) between two randomized groups at</measure>
    <time_frame>0, 24, and 72 hours after resuscitation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary neutrophil gelatinase-associated lipocalin (NGAL) after randomization and after resuscitation with trial fluid</measure>
    <time_frame>at 0,24 and 72 hours after resuscitation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary liver-type fatty acid binding protein (L-FABP)</measure>
    <time_frame>at 0,24 and 72 hours after resuscitation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential [Sepsis-related] Organ Failure Assessment (SOFA) Score. (excluding Glasgow Coma Score) at 72 hours after randomization.</measure>
    <time_frame>at 72 hours after randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of renal replacement therapy within 72 hours after randomization</measure>
    <time_frame>within 72 hours after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive without renal replacement therapy</measure>
    <time_frame>in 28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay for survivors sanctioned</measure>
    <time_frame>at 28 days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>balanced solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>for resuscitation in sepsis patients</description>
    <arm_group_label>normal saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ringer's Acetate</intervention_name>
    <description>for resuscitation in sepsis patients</description>
    <arm_group_label>balanced solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Who need fluid resuscitation in the Emergency Room (ER).&#xD;
&#xD;
          -  Who have fulfilled the criteria for sepsis/septic shock within the previous 24 hours&#xD;
             according to sepsis is defined as life-threatening organ dysfunction caused by a&#xD;
             dysregulated host response to infection.&#xD;
&#xD;
             o Patients with infection and resulted from a host's systemic inflammatory response&#xD;
             syndrome (SIRS) to infection are defined as sepsis if meet the criteria 2 or more of&#xD;
&#xD;
               -  Temperature &gt;38°C or &lt;36°C&#xD;
&#xD;
               -  Heart rate &gt;90/min&#xD;
&#xD;
               -  Respiratory rate &gt;20/min or PaCo2 &lt;32 mm Hg (4.3 kPa)&#xD;
&#xD;
               -  White blood cell count &gt;12000/mm3 or &lt;4000/mm3 or &gt;10% immature bands.&#xD;
&#xD;
          -  Patient who have Septic shock is a subset of sepsis in which underlying circulatory&#xD;
             and cellular/metabolic abnormalities are profound enough to substantially increase&#xD;
             mortality.&#xD;
&#xD;
             o Patients with septic shock can be identified with a clinical construct of sepsis&#xD;
             with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and&#xD;
             having a serum lactate level &gt;2 mmol/L (18 mg/dL) despite adequate volume&#xD;
             resuscitation.&#xD;
&#xD;
          -  AND where informed consent is obtainable either from the patient or by proxy (first&#xD;
             degree relative, spouse) if patients aren't in fully conscious status (eg.comatose,&#xD;
             drowsiness, irritable).&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic kidney disease (CKD) defined by baseline serum creatinine &gt; 2.0&#xD;
             in male and 1.5 in female.&#xD;
&#xD;
          -  Patients with End stage renal disease (ESRD) with or without renal replacement&#xD;
             therapy.&#xD;
&#xD;
          -  Patients with active cardiac disease : severe valvular heart, cardiomyopathy,&#xD;
             decompensated heart failure NYHA II-IV, severe pulmonary hypertension.&#xD;
&#xD;
          -  HIV/AIDs Patients.&#xD;
&#xD;
          -  Allergy towards 0.9% NaCl or Ringer's Acetate.&#xD;
&#xD;
          -  Any form of renal replacement therapy.&#xD;
&#xD;
          -  Intracranial bleeding within current hospitalization.&#xD;
&#xD;
          -  Therapy with corticosteroid or non steroidal anti-inflammatory substance.&#xD;
&#xD;
          -  Patients who predicted not to survive more than 24 hours.&#xD;
&#xD;
          -  Pregnant and lactating patients.&#xD;
&#xD;
          -  Withdrawal of active therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chulalongkorn university</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2017</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Nattachai Srisawat ,M.D.</investigator_full_name>
    <investigator_title>Associated professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

